FDA Brief

Warning letters Drugs

FDA warning letter to

Midlab Incorporated

High riskIssued Feb 15, 2023Posted Mar 14, 2023Division of Pharmaceutical Quality Operations II

FDA cited Midlab in Athens, Tennessee for manufacturing violations and unapproved, misbranded hand sanitizer and antibacterial soap drugs.

What happened

FDA inspected Midlab's drug manufacturing facility from August 1 to August 5, 2022. FDA found failures in current good manufacturing practice (CGMP): missing microbial batch testing, no investigation of out-of-specification stability results, use of expired benzalkonium chloride, and inadequate quality-unit oversight, process validation, and water-system validation. FDA also found MAXIM Instant Foam Hand Sanitizer was an unapproved new drug and several MAXIM antibacterial soap labels were misbranded.

What FDA found

  1. Midlab did not test each batch of hand sanitizer and antibacterial soap for objectionable microorganisms before release.

    21 CFR 211.165(b)
  2. Midlab did not investigate out-of-specification chloroxylenol stability results and used expired benzalkonium chloride in released hand sanitizer.

    21 CFR 211.192
  3. Midlab's quality control unit did not ensure adequate procedures, incoming component testing, or an ongoing stability program.

    21 CFR 211.22; 21 CFR 211.84(d)(1) and (d)(2); 21 CFR 211.166(a)
  4. Midlab did not validate its manufacturing process or water system and made unvalidated in-process adjustments.

    21 CFR 211.100(a)
  5. MAXIM Instant Foam Hand Sanitizer was marketed as an unapproved new drug with claims beyond the OTC antiseptic monograph, including S. aureus reduction.

    FD&C Act section 505(a), 21 U.S.C. 355(a); section 502(ee), 21 U.S.C. 352(ee)
  6. The antibacterial soap labels used PCMX instead of the established name chloroxylenol and did not include required net-content information in Spanish.

    21 CFR 201.66(c)(2); 21 CFR 201.15; 21 CFR 201.62(e)

What FDA wants

FDA tells Midlab to respond in writing within 15 working days with corrective actions and evidence, and recommends a qualified CGMP consultant if it intends to resume making drugs for the U.S. market.

Who should pay attention

  • companies that buy private-label or contract-manufactured hand sanitizers and antibacterial soaps
  • retailers and distributors selling OTC antiseptic products
  • quality teams at OTC drug manufacturers with similar testing and stability programs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk